15-day Paxlovid regimen safe but adds no clear long-COVID benefit

Preliminary results from a Scripps Research and eMed digital medicine study show an unexpectedly high proportion of COVID-19 rebound cases in untreated people, as well as those treated with Paxlovid.

© 2024 Thiratti. All rights reserved.